{
    "eid": "2-s2.0-85089654142",
    "title": "The influence of programmed cell death ligand 2 (PD-L2) expression on survival outcome and tumor microenvironment in diffuse large B cell lymphoma",
    "cover-date": "2020-01-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Hematology",
            "@code": "2720",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Oncology",
            "@code": "2730",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Cancer Research",
            "@code": "1306",
            "@abbrev": "BIOC"
        }
    ],
    "keywords": [
        "diffuse large B-cell lymphoma",
        "immune checkpoint",
        "programmed cell death 1",
        "Programmed cell death ligand 1",
        "programmed cell death ligand 2"
    ],
    "authors": [
        "San Krittikarux",
        "Kitsada Wudhikarn",
        "Nichthida Tangnuntachai",
        "Thamathorn Assanasen",
        "Narittee Sukswai",
        "Thiti Asawapanumas",
        "Chantiya Chanswangphuwana"
    ],
    "citedby-count": 4,
    "ref-count": 36,
    "ref-list": [
        "PD-1 and its ligands in tolerance and immunity",
        "PD-L2 is a second ligand for PD-1 and inhibits T cell activation",
        "The blockade of immune checkpoints in cancer immunotherapy",
        "PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations",
        "PD-1 expression and clinical PD-1 blockade in B-cell lymphomas",
        "PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas",
        "Programmed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns of expression in lymphoma subtypes",
        "Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies",
        "The prognostic and clinicopathological significance of PD-L1 expression in patients with diffuse large B-cell lymphoma: a meta-analysis",
        "CD3+/CD8+ T-cell density and tumoral PD-L1 predict survival irrespective of rituximab treatment in Chinese diffuse large B-cell lymphoma patients",
        "PD-L1 and tumor-associated macrophages in de novo DLBCL",
        "Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas",
        "PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies",
        "Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma",
        "Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study",
        "PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications",
        "PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell-inflamed phenotype",
        "Integrative analysis of PD-L1 DNA status, mRNA status and protein status, and their clinicopathological correlation, in diffuse large B-cell lymphoma",
        "Several immune escape patterns in non-Hodgkin's lymphomas",
        "Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas",
        "Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain",
        "Programmed death 1 is a marker of angioimmunoblastic T-cell lymphoma and B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia",
        "The expression and clinical relevance of PD-1, PD-L1, and TP63 in patients with diffuse large B-cell lymphoma",
        "Expression of PD-1 (CD279) and FoxP3 in diffuse large B-cell lymphoma",
        "Functional expression of programmed death-ligand 1 (B7-H1) by immune cells and tumor cells",
        "PD-L2 is expressed on activated human T cells and regulates their function",
        "Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification",
        "The 2016 revision of the World Health Organization classification of lymphoid neoplasms",
        "Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray",
        "Programmed cell death 1 and programmed cell death ligands in extranodal natural killer/T cell lymphoma: expression pattern and potential prognostic relevance",
        "Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells",
        "Clinicopathologic implication of PD-L1 and phosphorylated STAT3 expression in diffuse large B cell lymphoma",
        "Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells",
        "A Quantitative comparison of antibodies to programmed cell death 1 ligand 1",
        "A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non-small cell lung cancer",
        "PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome"
    ],
    "affiliation": {
        "affiliation-city": "Bangkok",
        "@id": "60028190",
        "affilname": "Chulalongkorn University",
        "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
        "affiliation-country": "Thailand"
    },
    "funding": [
        "Ratchadapisek Sompotch Foundation",
        "Cancer Run Research Foundation"
    ]
}